MetaCap

Alzamend Neuro (ALZN) vs Bio Green Med Solution (BGMS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alzamend Neuro is the larger company by market cap ($3.7 million vs $3.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALZN-43.37%BGMS-34.94%
+21%-13%-46%
Oct 7, 20261 yearNov 20, 2026
ALZN-42.10%BGMS-34.86%
+16%-15%-45%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALZN versus BGMS key metrics
MetricALZNBGMS
Share price$0.7758$0.553
Market cap$3.74M$3.66M
1-day change-23.94%-9.48%
EPS (TTM)$-2.30$-3.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-8.77M$-3.00M
52-week high$2.54$2.80
52-week low$0.754$0.55
Distance from 52-week high-69.40%-80.25%
Analyst consensusnone—
Avg. price target upside+3251.38%—
Average volume70.27K76.12K
Shares outstanding4.83M6.62M
Employees4—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alzamend Neuro

ALZN stock →

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Bio Green Med Solution

BGMS stock →

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems.

Health Care · Biotechnology: Pharmaceutical Preparations

ALZN vs BGMS FAQ

Which is bigger, Alzamend Neuro or Bio Green Med Solution?

Alzamend Neuro (ALZN) is larger, with a market capitalization of $3.74M compared with $3.66M for Bio Green Med Solution (BGMS).

Are Alzamend Neuro and Bio Green Med Solution in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons